Literature DB >> 12174447

Interstitial brachytherapy in the head and neck region: when has imaging for treatment planning to be performed?

Jürgen Schultze1, Ralf Schneider, Bernhard Kimmig, György Kovacs.   

Abstract

BACKGROUND AND
PURPOSE: The relation of real and virtual anatomy in 3D treatment planning is influencing the quality of a brachytherapy treatment. Aim of this study was to evaluate how far prior to plastic tube implantation for fractionated interstitial brachytherapy performed imaging is appropriate for treatment planning purposes in regard to iatrogenic, morphologic changes of anatomy.
MATERIAL AND METHODS: Until April 1, 2001, 51 patients were included in this examination. Primary tumor sites were in the base of tongue (35), oro-/hypopharynx (9), floor of the mouth (4) as well as soft palate (3). Cross section imaging (MRI) in all the patients was performed before and three to six days after implantation of plastic tubes. To evaluate the morphologic alterations due to implant procedure and postimplant edema, distances were measured between two anatomically clearly defined landmarks of whom one had to be invariant to applicator implantation.
RESULTS: Between two anatomical landmarks initially mean standard distances were measured: Vertebra-pharyngeal mucosa 1.46 cm, mandibular-pharyngeal wall 3.14 cm, mandibular tip-base of tongue 5.12 cm, tongue width 4.77 cm. The comparison of pre- and postimplant MRI then revealed mean distance alterations: Vertebra-pharyngeal mucosa 3.1 mm, mandibular-pharyngeal wall 4.2 mm, mandibular tip-base of tongue 5.9 mm, tongue width 6.0 mm.
CONCLUSIONS: Mean applicator induced anatomic deviations between 3.1 and 6.0 mm compared to pre-implant anatomy, can severely change the target dose distribution. Basis of 3D-treatment planning therefore has to be always postimplant cross sectional imaging with adequate soft tissue depiction.

Entities:  

Mesh:

Year:  2002        PMID: 12174447

Source DB:  PubMed          Journal:  Rontgenpraxis        ISSN: 0035-7820


  3 in total

1.  Edema worsens target coverage in high-dose-rate interstitial brachytherapy of mobile tongue cancer: a report of two cases.

Authors:  Ken Yoshida; Hideya Yamazaki; Tadayuki Kotsuma; Hironori Akiyama; Tadashi Takenaka; Koji Masui; Yasuo Yoshioka; Yasuo Uesugi; Taiju Shimbo; Nobuhiko Yoshikawa; Hiroto Yoshioka; Takumi Arika; Eiichi Tanaka; Yoshifumi Narumi
Journal:  J Contemp Brachytherapy       Date:  2017-01-16

2.  Quality assurance during interstitial brachytherapy: in vivo dosimetry using MOSFET dosimeters.

Authors:  Corinna Melchert; Tamer Soror; György Kovács
Journal:  J Contemp Brachytherapy       Date:  2018-06-28

3.  A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer.

Authors:  Ken Yoshida; Tadayuki Kotsuma; Hironori Akiyama; Hideya Yamazaki; Tadashi Takenaka; Koji Masui; Yutaka Tsujimoto; Naoya Murakami; Yasuo Uesugi; Taiju Shimbo; Nobuhiko Yoshikawa; Hiroto Yoshioka; Mio Nakata; Takumi Arika; Yuji Takaoka; Eiichi Tanaka; Nikolaos Tselis
Journal:  J Contemp Brachytherapy       Date:  2019-12-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.